Anthracyclines cause cumulative dose-dependent cardiotoxicity leading to heart failure, requiring specific methods for detection, prevention, and treatment.
May support enhanced cardiac surveillance in anthracycline recipients; leaves open optimal prevention and treatment strategies.
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
No takes yet. Share an insight, caveat, or question.
Волкова et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: